Revelation Biosciences REVB
NASDAQ REVB
$3.57 -0.18 (-4.78%)
As of: Oct 21, 2026 · 2:21 PM EDT

Revelation Biosciences (REVB) Notes Payables (2020 - 2021)

Updated

Revelation Biosciences' Notes Payables came in at $774,345 for Q4 2021.

Analysis

Revelation Biosciences (REVB) Notes Payables (2020 - 2021) Analysis & Trends

  • The Q4 2021 figure represents the lowest quarterly Notes Payables since Q3 2020.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.92 Bn 1,105.50 Bn 19.71 Bn
2 Johnson & Johnson 617.57 Bn 536.10 Bn 17.26 Bn
3 AbbVie 501.37 Bn 474.48 Bn 12.70 Bn
4 Merck 367.96 Bn 322.33 Bn 12.21 Bn
5 Novartis Ag 297.98 Bn 261.97 Bn 11.24 Bn
6 Astrazeneca 261.45 Bn 235.14 Bn 12.86 Bn
7 Amgen 236.30 Bn 191.70 Bn 7.24 Bn
8 Gilead Sciences 190.27 Bn 164.46 Bn 6.22 Bn
9 Pfizer 169.65 Bn 116.29 Bn 10.94 Bn
10 Revelation Biosciences 13.67 Mn -35.35 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2021 774,345.00
Sep 30, 2020 125,000.00
API Access

Revelation Biosciences Notes Payables API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=notes-payables&ticker=REVB&period=max&api_key=YOUR_API_KEY